Recruiting NCT04075305

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

Trial Parameters

Condition Oncology

Sponsor UMC Utrecht

Study Type OBSERVATIONAL

Phase N/A

Enrollment 8,000

Sex ALL

Min Age 18 Years

Max Age N/A

Start Date 2019-02-01

Completion 2030-02-01

All Conditions

Oncology Breast Cancer Prostate Cancer Gynecologic Cancer Brain Tumor Brain Cancer Gynecologic Tumor Prostate Tumor Prostate Neoplasm Breast Tumor Radiation Toxicity Quality of Life Rectal Cancer Rectal Tumor Rectal Neoplasms Lung Cancer Lung Tumor Lung Neoplasm Esophageal Cancer Esophagus Cancer Esophageal Tumor Esophageal Neoplasm Esophagus Tumor Esophagus Neoplasm Pancreatic Cancer Pancreatic Tumor Pancreatic Neoplasms Head and Neck Cancer Head and Neck Neoplasms Head and Neck Tumor Tumor Neoplasms Bladder Cancer Bladder Neoplasm Liver Cancer Liver Neoplasms Liver Metastases Oligometastases

Interventions

Radiation therapy

Brief Summary

The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.

Eligibility Criteria

Inclusion Criteria: * Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac; * Patient provides written, informed consent; * Patient is 18 years old or older. Exclusion Criteria: * MRI exclusion criteria, including * MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.

Related Trials

NCT06326411

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

View Trial →

NCT06201884

Efficacy of Adapted Physical Activity on a Walking Platform in Elderly Patients HOspitalized for Can

View Trial →

NCT06222801

The 1st Tumor CytokinoTherapy Database (TCTD-1)

View Trial →

VIEW ON CLINICALTRIALS.GOV ↗ MORE ONCOLOGY TRIALS